TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05973552

Intervention type: OTHER
Intervention: CO-rebreathing
Description: In the CO-rebreathing method, a dedicated apparatus is used for inhaling and rebreathing a very small bolus of CO through a spirometer for \~2 min, which is absorbed through the lungs and binds to Hb, and then the increase of HbCO content of blood is measured 8 min after the CO inhalation. The increase of COHb in blood samples can then be used to precisely calculate Hb mass and blood volume

Intervention type: OTHER
Intervention: CO-rebreathing
Description: In the CO-rebreathing method, a dedicated apparatus is used for inhaling and rebreathing a very small bolus of CO through a spirometer for \~2 min, which is absorbed through the lungs and binds to Hb, and then the increase of HbCO content of blood is measured 8 min after the CO inhalation. The increase of COHb in blood samples can then be used to precisely calculate Hb mass and blood volume

Intervention type: OTHER
Intervention: Oral iron isotope administration (54Fe)
Description: Participants randomly assigned to the sub-group, will receive 54Fe with a test meal in the second and third trimester for assessment of dietary iron absorption

Intervention type: OTHER
Intervention: Intravenous iron isotope administration (58Fe)
Description: Participants randomly assigned to the sub-group, will receive intravenous 58Fe in the second and third trimester for assessment of erythrocyte iron incorporation
Study: NCT05304650

Intervention type: DEVICE
Group type: OTHER
Intervention: iTEAR100
Description: Controlled Stimulation External Nasal Nerve to stimulate tear production
Study: NCT06071767

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdOx1.tHIVconsv1
Description: Administered as 0.4 mL intramuscularly (IM) at Week 0

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdOx1.HIVconsv62
Description: Administered as 0.3 mL IM at Week 0

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA.tHIVconsv3
Description: Administered as 0.3 mL IM at Week 4

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA.tHIVconsv4
Description: Administered as 0.5 mL IM at week 4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vesatolimod (VES)
Description: VES 6 mg administered orally once every 2 weeks for two doses, then VES 8 mg once every 2 weeks for 8 doses. Dose escalation may be held or the 8 mg dose may be reduced for intolerability for weeks 6 through 24.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-5423
Description: Administered via intravenous (IV) infusion at week 7

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-2872
Description: Administered via IV infusion at week 7

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA.tHIVconsv4
Description: Administered 0.5 mL IM at week 60

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebos for vaccines, VES, and bnAbs
Study: NCT05301920

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Elexir (trigeminal nerve electrical stimulator)
Description: Elexir performs a personal electrical stimulation around the trigeminal nerves for 4weeks (6 times/week), 20 minutes each time.
Study: NCT05060705

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efesovir
Description: Antiviral therapy of COVID19 with Efesovir oral solution in dose 0.125 ml / kg two times per day. Duration of treatment is 5 - 10 days, depending on the severity of the disease.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Efesovir
Description: Antiviral therapy of COVID19 with Efesovir oral solution in dose 0.125 ml / kg two times per day. Duration of treatment is 5 - 10 days, depending on the severity of the disease.
Study: NCT05742997

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PartoSure
Description: Diagnostic Kit for the Detection of Placental Alpha-Microglobulin-1

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fetal Fibronectine
Description: Diagnostic Kit for the Detection of Fetal Fibronectine
Study: NCT04577729

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogenic Fecal Microbiota Transplantation
Description: Patients receiving stool from prior malignant melanoma (MM) patients in remission for at least 1 year after Checkpoint Inhibitor Treatment.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Autologous Fecal Microbiota Transplantation
Description: Patients receiving their own stool in terms of sham FMT.
Study: NCT06395233

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BetterPoints App
Description: The BetterPoints app is a smartphone application that uses incentives and gamification to motivate physical activity.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BetterPoints App
Description: The BetterPoints app is a smartphone application that uses incentives and gamification to motivate physical activity.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BetterPoints App
Description: The BetterPoints app is a smartphone application that uses incentives and gamification to motivate physical activity.
Study: NCT04662944

Intervention type: DRUG
Intervention: brolucizumab
Description: There was no treatment allocation. Patients administered Brolucizumab by prescription that started before inclusion of the patient into the study were enrolled.

Intervention type: DRUG
Intervention: ranibizumab
Description: There was no treatment allocation. Patients administered Ranibizumab by prescription that started before inclusion of the patient into the study were enrolled.

Intervention type: DRUG
Intervention: aflibercept
Description: There was no treatment allocation. Patients administered Aflibercept by prescription that started before inclusion of the patient into the study were enrolled.
Study: NCT06490276

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gait training with biofeedback
Description: Gait training include treadmill and overground walking. The biofeedback device system will provide real-time feedback on hip extension angles.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gait training without biofeedback
Description: Gait training include treadmill and overground walking.
Study: NCT05239611

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: The intervention for all participants will be delivered by two pulmonary rehabilitation coaches (PR-coach) including a registered respiratory therapist and clinical registered dietitian who've been trained in exercise training as recommended by the AACVPR and American College of Sports Medicine (ACSM). Each TR participant will be assigned a PR-coach, and receive one weekly exercise consulting session during the 12-week intervention.
Study: NCT05146245

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic Drug Monitoring
Description: Physician receives dosing advice based on risperidone plasma level.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone plasma level
Description: Plasma levels of risperidone and 9-OH risperidone are measured in a Dried Blood Spot.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Risperidone plasma level
Description: Plasma levels of risperidone and 9-OH risperidone are measured in a Dried Blood Spot.
Study: NCT05054647

Intervention type: OTHER
Intervention: psychometric questionnaires
Description: Perceived Stress Scale (PSS-10); Trier-Inventory on Chronic Stress; State/Trait Anxiety Inventory (STAI); AVEM-Work-related behaviour and experience pattern; Maslach Burn-out Inventory - Human Services Survey (MBI - HSS) health-related anxiety: Whiteley Index (WI)
Study: NCT06428084

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: 4 mg of ondansetron intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Haloperidol
Description: 1 mg of Haloperidol intravenously
Study: NCT05311670

Intervention type: BEHAVIORAL
Intervention: Patient-reported outcomes monitoring
Description: o Patient-reported outcomes will be collected from patients through web or telephone and alerts sent to providers.
Study: NCT05511974

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: BASET score
Description: The patients were divided into two groups. Group I (study group): consist of sixty-three patients having OSA. Group II (control group): consist of eighty-one non-OSA patients
Study: NCT04137120

Intervention type: DRUG
Intervention: Aflibercept (BAY86-5321, Eylea)
Description: Intravitreal injection of aflibercept as scheduled by treating physician
Study: NCT06508918

Intervention type: DRUG
Intervention: Betametasona
Description: pressure pain threshold values of the most painful area will be recorded with a manual algometer

Intervention type: DRUG
Intervention: Betametasona
Description: pressure pain threshold values of the most painful area will be recorded with a manual algometer
Study: NCT06448702

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: wet wrap therapy
Description: Steps for wet wrap therapy After bath/shower with emollients, pat to remove excess water on body and apply the emollient and/ or steroid cream liberally on the affected area to enhance water absorption and seal in moisture Put wet wrap garment in lukewarm water, squeeze water out of the wet wrap garment, take them out without dribbling of water and then apply on the affected area Put on another layer of dry garments/ warm clothing to cover the wet wrap garments and wear usual clothing as needed Check regularly and keep the wet wrap garments underneath damp with water sprayer or wet towel if necessary Patient is suggested to apply emollients frequently throughout the day to maintain the effect

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: External compression counter-pulsation (EECP)
Description: External compression counter-pulsation (EECP) is a compression/decompression non-invasive device (Stendo Pulsewave ® V3 CE certificate class IIa) used for lower part of the body (legs, thighs and buttock/hips) to reproduce and stimulate the natural physiological pulsations and the physical shear stress force.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: External compression counter-pulsation (EECP)
Description: External compression counter-pulsation (EECP) is a compression/decompression non-invasive device (Stendo Pulsewave ® V3 CE certificate class IIa) used for lower part of the body (legs, thighs and buttock/hips) to reproduce and stimulate the natural physiological pulsations and the physical shear stress force.
Study: NCT05296642

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate Cycling
Description: Using the recumbent bicycle (95Ri, Life Fitness, Illinois) participants will be asked to sustain a moderate pace of 13 - 16 for 20 minutes of perceived exertion range using the Borg rate of perceived exertion scale (RPE).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate Cycling
Description: Using the recumbent bicycle (95Ri, Life Fitness, Illinois) participants will be asked to sustain a moderate pace of 13 - 16 for 20 minutes of perceived exertion range using the Borg rate of perceived exertion scale (RPE).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personalized Tourniquet System
Description: An automated personalize tourniquet system (Delfi Medical, Inc., Vancouver, BC, Canada) will be used to perform blood flow restriction during BFR+AE. This system has a dual-purpose tourniquet cuff (11.5 x 86 cm) connected by airtight hose tubing to a personalized tourniquet device. The device automatically measures LOP and regulated pressure during exercise within clinically acceptable limits. Participants will be asked to lie in supine and a non-shedding stockinette protection sleeve will be placed at bilateral proximal thighs. Following, a tourniquet cuff will be placed bilaterally around the protection material and connected to the airtight hose tube.
Study: NCT05150600

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Inverse Ratio Ventilation
Description: The inspiratory to expiratory (I:E) ratio will be reversed to be 2:1 during mechanical ventilation
Study: NCT06044207

Intervention type: DIAGNOSTIC_TEST
Intervention: Pittsburgh sleep quality index
Description: The scale is suitable for evaluating sleep quality in patients with sleep disorders and psychiatric disorders, as well as for assessing sleep quality in the general population.

Intervention type: DIAGNOSTIC_TEST
Intervention: Pittsburgh sleep quality index
Description: The scale is suitable for evaluating sleep quality in patients with sleep disorders and psychiatric disorders, as well as for assessing sleep quality in the general population.

Intervention type: DIAGNOSTIC_TEST
Intervention: Self-rating depression scale
Description: The scale is easy to use, can fairly intuitively reflect whether the patient has depression and the degree of depression, has been widely used in outpatient gross screening, mood state assessment.

Intervention type: DIAGNOSTIC_TEST
Intervention: Self-rating depression scale
Description: The scale is easy to use, can fairly intuitively reflect whether the patient has depression and the degree of depression, has been widely used in outpatient gross screening, mood state assessment.

Intervention type: DIAGNOSTIC_TEST
Intervention: Montreal Cognitive Assessment
Description: The scale is a tool used for rapid screening of mild cognitive dysfunction to identify patients with preoperative cognitive dysfunction

Intervention type: DIAGNOSTIC_TEST
Intervention: Montreal Cognitive Assessment
Description: The scale is a tool used for rapid screening of mild cognitive dysfunction to identify patients with preoperative cognitive dysfunction
Study: NCT05505136

Intervention type: DEVICE
Intervention: Arrhythmia Management System (AMS)
Description: Retrospective collection of data related to subjects who participated in the MAPS 90D0234 study and had a medication change reported will wearing the AMS device.
Study: NCT05421312

Intervention type: DRUG
Group type: OTHER
Intervention: sampling blood
Description: During the reimplantation, 3 serum samples will be taken at different timepoint during the procedure.

Intervention type: DRUG
Group type: OTHER
Intervention: sampling blood
Description: During the reimplantation, 3 serum samples will be taken at different timepoint during the procedure.

Intervention type: DRUG
Group type: OTHER
Intervention: Sampling synovial fluid
Description: During the reimplantation 1 synovial fluid sample will be taken prior to incision.
Study: NCT05048992

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ELDOA method
Description: group A will receive

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Post-facilitation stretching
Description: Group B will receive
Study: NCT05718609

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rabeprazole
Description: proton-pump inhibitor (PPI)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole
Description: proton-pump inhibitor (PPI)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole
Description: proton-pump inhibitor (PPI)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colloidal Bismuth Pectin Granules
Description: Gastric mucosal protective drug with anti-H. pylori effect

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colloidal Bismuth Pectin Granules
Description: Gastric mucosal protective drug with anti-H. pylori effect

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colloidal Bismuth Pectin Granules
Description: Gastric mucosal protective drug with anti-H. pylori effect

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: Antibiotic for H. pylori eradication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: Antibiotic for H. pylori eradication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: Antibiotic for H. pylori eradication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furazolidone
Description: Antibiotic for H. pylori eradication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furazolidone
Description: Antibiotic for H. pylori eradication

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin
Description: Antibiotic for H. pylori eradication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: Antibiotic for H. pylori eradication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: Antibiotic for H. pylori eradication
Study: NCT05530109

Intervention type: OTHER
Intervention: Neuropsychological screening and high resolution EEG recording
Description: Each participant will be assessed with a battery of neuropsychological tests including Epitrack, the Raven's progressive matrice, the MoCA, the D2-R test, the BDI-II test, the STAI and the Qolie-31. Then, a prolonged EEG recording at rest and during an attentional task (the ANT) will be realized

Intervention type: OTHER
Intervention: Neuropsychological screening and high resolution EEG recording
Description: Each participant will be assessed with a battery of neuropsychological tests including Epitrack, the Raven's progressive matrice, the MoCA, the D2-R test, the BDI-II test, the STAI and the Qolie-31. Then, a prolonged EEG recording at rest and during an attentional task (the ANT) will be realized
Study: NCT06438874

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Test
Description: Exercise capacity will be measured as peak oxygen consumption (peakVO2) using an incremental exercise test on a cycle ergometer with an open-circuit spirometry system (TrueOne, Parvo Medics, Sandy, UT) to analyze expired gases. Exercise testing will follow the American College of Sports Medicine and American Heart Association guidelines. The investigators will use a graded protocol, starting with a warm-up at 0 watts for 5 minutes, followed by 15 watt increments every 2 minutes until volitional fatigue.
Study: NCT06304389

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electroencephalography, electrocardiogram, pupillometry, evoked potentials, light administration
Description: Recording of the electrical activity of the brain, of the heart. Pupil size will be analyzed. The effect of blue light administration will be assessed on those parameters.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: transcutaneous vagus nerve stimulation, electroencephalography, pupillometry, electrocardiogram, light administration
Description: Transcutaneous vagus nerve stimulation will be performed in helathy subjects, as well as the recording of the electrical activity of the brain, and of the heart. Pupil size will be analyzed. The effect of blue light administration will be assessed on those parameters.
Study: NCT06261970

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Connect
Description: Community level enhancements
Study: NCT04897802

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental: GLP1-RA (exenatide) administration
Description: a single dose of 10 mcg of GLP-RA (exenatide) will be administered subcutaneously and samples to assess OT secretory patterns will be collected over 2 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control: Placebo administration
Description: Sodium Chloride 0.9% will be administered subcutaneously at equivalent volume than 10 mcg of exenatide
Study: NCT05421312

Intervention type: DRUG
Group type: OTHER
Intervention: Sampling synovial fluid
Description: During the reimplantation 1 synovial fluid sample will be taken prior to incision.

Intervention type: DRUG
Group type: OTHER
Intervention: Sampling bone tissue
Description: During the reimplantation 2 cortical bone samples will be taken at different timepoints during the procedure.

Intervention type: DRUG
Group type: OTHER
Intervention: Sampling bone tissue
Description: During the reimplantation 2 cortical bone samples will be taken at different timepoints during the procedure.
Study: NCT04897477

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacytidine, Bendamustine and Piamprizumab
Description: Azacytidine by means of subcutaneous injection, Bendamustine and Piamprizumab intravenous infusion
Study: NCT05773521

Intervention type: PROCEDURE
Intervention: SILAP (single incision laparoscopic appendectomy)
Description: Appendectomy performed through transumbilical single access laparoscopy, consisting in the removal of the appendix.
Study: NCT06001112

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cheek acupuncture
Description: Based on the theory of holography and the theory of the Great Sanjiao, the acupoints were chosen under the guidance of the foundation of cheek acupuncture, selecting bilateral Sanjiao acupoints, bilateral head acupoints, foot and ankle acupoints on the affected side, and matching acupuncture points for local strengthening of the foot and ankle acupuncture points, using the triangular needle strengthening method. The treatment was performed with the patient lying on his back in a comfortable position, with routine local disinfection, rapid transdermal needle entry to the acupuncture points, and needle discharge after 30 minutes of needle retention, after which the needle hole was compressed with a cotton ball for a few moments.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoricoxib
Description: etoricoxib 120mg
Study: NCT04570501

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Angiotensin-(1-7)
Description: Ang (1-7) administered by continuous intravenous (IV) infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (normal saline) administered by continuous intravenous (IV) infusion
Study: NCT06090851

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: herbal nitrate Pralines with nitrate
Description: consumption of herbal pralines with nitrate

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: herbal nitrate Pralines without nitrate
Description: consumption of herbal pralines without nitrate
Study: NCT05530720

Intervention type: OTHER
Intervention: Cross-sectional survey
Description: No intervention.
Study: NCT05198336

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated COVID-19 Vaccine
Description: 600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated COVID-19 Vaccine
Description: 600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection
Study: NCT05301868

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multidomain intervention
Description: For 24 weeks, participants will receive cognitive training twice a week, exercise 3 times a week, nutrition education 12 times, and education about vascular risk factor management every 2 weeks using the tablet PC application.